Page 344 - ASHG 2012 Annual Meeting Program Guide

SPEAKER AND AUTHOR DISCLOSURES
331
SPEAKER/AUTHOR DISCLOSURES
Jensen, T. J., Sequenom, Inc. - 1, 3 (3014)
Jeong, K., Agilent Technologies - 3 (3459)
Jiang, R., Williams LifeSkills, Inc. - 1, 4 (2481)
Johnson, F. K., Amicus Therapeutics - 1, 3 (732)
Joun, D., Life Technologies - 3 (1246)
Kaper, F., Illumina, Inc. - 3 (596)
Karczewski, K. J., Personalis - 10 (562)
Kennedy, C. J., Good Start Genetics - 1, 3, 10 (3640)
Kitzman, J. O., Univ of Washington - 10 (74)
Kong, A., deCode Genetics - 3 (Session 75)
Kormanik, K., Hyperion Therapeutics - 2; NIH - 2 (662)
Kutalik, Z., GlaxoSmithKline - 12 (1387)
Laberge, A. M., Fourth Dimension Spine LLC (NYC,
USA) - 2 (1784)
Langmore, J. P., Rubicon Genomics, Inc. - 1, 3, (3689)
Laurance, M., Ingenuity - 3 (3560)
Lebo, R., USPTO-application - 10 (2972)
Le Clerc-Blain, J., Cree Board of Health and Social
Services of James Bay - 14 (1733)
Ledbetter, D. H., Roche Nimblegen - 5; Celula - 5
(
Session 77)
Letra, A., NIH - 2 (1936)
Levy, B., Natera - 1, 5, 11 (73)
Li, C., Life Technologies - 3 (3714)
Li, H., The National Natural Science Foundation of
China 30770106 - 2 (798)
Li, M., Life Technologies - 14 (399)
Lih, C.-J., Life Technologies - 12 (1068)
Lins, T. C. L., CNPq - 2; CAPES - 2; FAP-DF - 14 (3272)
Liu, P., New England Biolabs - 3 (3715)
Loomis, E. W., Pacific Biosciences of California, Inc -
9, 12 (2633)
Lorget, F., BioMarin - 3, 10; INSERM U781 - 12 (763)
Luke, M. M., Celera - 3, 4 (1603)
Luo, M., Mount Sinai School of Medicine - 10 (1777)
Lyon, E., Novartis - 5; Complete Genomics - 1, 5;
Oregon Health Sciences - 14; National Society of
Genetic Counselors - 14; University of Utah/ARUP
Laboratories- 3; NICHD/NIH- 2; NHGRI/NIH- 2
(
Session 3)
Madhusoodanan, J., NextBio - 3 (1183)
Mancini-DiNardo, D., Myriad Genetic Laboratories,
Inc. - 1, 3 (1021)
Manokhina, I., Partnership for Clean Competition - 2
(1760)
Marques, F. A., CNPq - 2; CAPES - 2; FAP-DF - 14 (1880)
Martin, C. L., Emory Genetics Laboratory - 3; NIH - 2;
Simons Foundation - 2 (Session 17, Session 77)
Martis, S., MRC Holland - 3 (652)
Marziali, A., Boreal Genomics - 3, 4, 6, 10 (1264)
Matsunami, N., Lineagen Inc. - 1, 2 (2397)
McDonald, M. N., NIH - 2; GlaxoSmithKline funded
ECLIPSE study - 2 (2249)
McInerney, P., Illumina, Inc. - 1, 3; Epicentre, Inc.
(
an Illumina company) - 3 (3697)
McKay, G. J., Nutrasight Consultancy Limited - 5 (1897)
Mehta, G. R., Locus Development - 1, 3, 4, 10, 13 (3692)
Menashe, I., MindSpec - 3 (446)
Meredith, G., Life Technologies Corp - 1, 3 (3717)
Mikula, M., Dept Molecular Genetics, Quest
Diagnostics Nichols Inst, San - 1, 3 (2260)
Miyagawa, T., Clinical Trial Operations Division, Site
Support Institute C - 3 (2656)
Morales, A., Informed Medical Decisions, Inc. -
5 (1681)
Moreno, T., Pathway Genomics - 1, 3, 12 (Session 9)
Morford, L., American Association of Women Dentists -
2;
Southern Association of Orthodontists - 2 (1147)
Morgan, T., Biomarin - 15; Clinical trial support for all
but the first author (730)
Mountain, J., 23andMe, Inc. - 1, 3 (Session 9)
Mowery-Rushton, P. A., Signature Genomic
Laboratories, PerkinElmer, Inc., Spokane, - 3 (3101)
Moya, P. R., F. Hoffmann-La Roche AG - 3 (261)
Muller, R., Biomatrica - 3 (3720)
Mullins, M. E., 23andMe, Inc. - 3 (2127)
Munafo, D., New England Biolabs, Inc - 3 (512)
Musci, T., Ariosa Diagnostics - 1, 3 (2978)
Myres, N., AncestryDNA - 3 (3321)
Neale, B. M., Illumina - 14 (2618)
Nestrasil, I., Shire HGT - 2, 5 (714)
Nguyen-Nielsen, M., Edimer Pharmaceuticals
(
MA, USA) - 2 (1565)
Nicholls, K., GSK - 1, 3, 14; Amicus - 1, 3, 11, 14 (745)
Niemi, A.-K., United Mitochondrial Disease
Foundation - 2 (744)
Nishida, A., JCR Pharmaceuticals - 3 (781)
Normanno, N., Life Tecnologies - 12 (1060)
Noto, K., Ancestry.com - 1, 3; AncestryDNA - 1 (3365)
Nurmi, E. L., BioMarin - 5; Novartis - 5; Seaside
Therapeutics - 2; Roche - 2 (639)
Nussbaum, R. L., Complete Genomics -
1, 5 (
Session 77)
Oeth, P., Sequenom, Inc. - 1; Sequenom Center for
Molecular Medicine - 3 (3016)
Oliver, J. S., Nabsys - 1, 3, 4, 10, 13 (3656)
Ong, F. S., National Institutes of Health - 2; Cedars-
Sinai Medical Center - 2; Complete Genomics,
Inc. - 15; Illumina, Inc. - 15; Stock Ownership
(
not stock options as in 1) (130)
O’Roak, B. J., Yale University - 10 (10)
Ota, V. K., FAPESP - 2 (2533)
Pallone, N. L., BioMarin - 2; Nutricia - 2; Vitaflo - 2;
Mead Johnson - 2 (742)
Pare, G., Boehringer Ingelheim Pharma Inc. - 2, 5, 8,
12 (617)
Patsalis, P., NIPD Genetics Ltd. - 10 (3017)
Peltekova, V., OICR - 2; CIHR - 2; Ontario Research
Funds - 2 (1093)
Peng, Q., QIAGEN - 3 (1263)
Peng, X., Life Technologies - 3 (3698)
Perez-Jurado, L. A., qGenomics - 6, 11 (2711)
Pericak-Vance, M. A., Artic Dx, Inc - 10 (Session 7)
Peterschmitt, M. J., Genzyme - 3 (773)
Phelan, M., NuGEN Technologies, Inc. - 1, 3 (3699)
Porreca, G. J., Good Start Genetics - 1, 3, 10 (3680)
Potocki, L., Baylor College of Medicine - 3 (Session 28)
Pour-Jafari, H., Hamadan Univ Med Sci - 3 (860)
Powers, N. R., JS Genetics, Inc - 4, 7, 10, 11, 13 (2010)
Rabinowitz, M., Natera, Inc. - 3, 1, 10 (3018)
Rath, M., Life Technologies Inc. - 3, 10 (532)
Ray, F. A., KromaTiD Inc. - 1, 3, 4, 10 (948)
Raz, T., GnuBio - 3 (3700)
Rehm, H. L., Partners Healthcare - 3; Complete
Genomics - 11; GenomeQuest - 11; Illumina - 12
(
Session 77)